In April 2026, an interesting study appeared in BMC Medical Education in which the focus is not so much on the effects of psilocybin, but on something that is at least as decisive for the outcome of a session: the quality of the guidance. The study titled Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression looks specifically at how well facilitators are prepared for their role within a clinical setting.
What makes this study special is that it is one of the first studies to systematically examine the training of supervisors within a psilocybin trial. While most studies focus on the substance itself, this study zooms in on the human factor. And that is precisely where the difference often lies.
Psilocybin studies make use of facilitators (therapists or nurses) who prepare patients, guide them during the dosing session, and support them during integration sessions. Little is known about which skills are required, which professional groups are suitable, and what a training course should look like.. The research published in April 2026 in BMC Medical Education describes and evaluates a 15-week training program for nine nurses who became facilitators in the CAPSI project. The goal was both to describe the content of the training and to measure the effects on their skills and experiences..
The program, designed by two researchers from the CAPSI team (DS Stenbæk and M. Beckman), consisted of two parts.:
During the training, participants had access to an online platform with materials. Preparatory reading material was provided for each webinar..
The 13-item survey revealed the following:
| Item (summarized) | Average score (1–5) | Important finding |
|---|---|---|
| Sufficient knowledge to start treatment | 3.56 ± 0.53 | Participants felt that they gained sufficient knowledge, but were not fully prepared. |
| Sufficient skills to start treatment | 3.67 ± 0.50 | People felt slightly more competent, but self-confidence remained limited. |
| More training days would be useful | 4.56 ± 0.73 | The majority wanted more training days. |
| Need more practical training | 4.33 ± 0.87 | Practical exercises were missed; webinars mainly provided theory. |
| More online training desired | 1.44 ± 0.73 | People actually preferred less online and more physical training. |
| More in-person training desired | 4.89 ± 0.33 | Very strong preference for physical training. |
| Felt adequately prepared | 3.11 ± 0.78 | Despite training, people still felt insecure. |
Main themes from the free text:
The MITI analysis found a significant improvement in only one of the two global scores; Partnership rose from an average of 2.11 to 2.56 (p = 0.046, r = −0.47). Empathy showed an increase (1.22 to 1.89) with a large effect size (r = −0.50) but did not reach statistical significance. For the behavior counters, predominantly medium effect sizes were observed (for example Simple reflection from 0.44 to 1.67) but no significant changes. It is striking that the nurses primarily provided information (Giving information ≈ 20 utterances per role-play) and did not participate in confrontational or persuasive interventions..
| Aspect | Detail |
|---|---|
| Full title | Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial. |
| Goal | Compares the effect of a single oral dose psilocybin 25 mg immediately 1 mg active placebo on depressive symptoms in cancer patients with major depressive disorder (MDD). |
| Design | Multicenter RCT (2:1 randomization, double-blind, phase II). Inclusion of 100 patients between 2024–2025. Each patient receives one dosing session (7–9 hours) plus psychotherapeutic support: two preparation sessions and three integration sessions.. |
| Primary outcome | Change in depression score (Montgomery & Åsberg Depression Rating Scale or PHQ‑9) six weeks after dosing. |
| Accompaniment | All facilitators are nurses who have completed 15-week training (see above) and are supported by a nurse assistant during dosing.. |
| Registration | EudraCT 2023‑505532‑35‑00; ClinicalTrials.gov NCT06319378. Registration date 8 November 2023. |
| Recruitment Status (April 19, 2026) | Recruitingclinicaltrials.gov. |
| Locations | Four Swedish centers (Stockholm, Uppsala, Gothenburg, Örebro)clinicaltrials.gov. |
| Inclusion and exclusion criteria | Enrollment of adults (20–80 years) with cancer-related MDD, PHQ‑9 ≥ 10; at least one month since diagnosis; at least 12 months estimated lifespan; exclusion in case of recent antidepressant treatment, severe cardiovascular disease, psychedelic use, or severe psychiatric history. |
It Karolinska Institutet outlines the broader context: 70,000 Swedes are diagnosed with cancer annually; approximately one-third develop depression, and there are no specific antidepressant treatments.. CAPSI is recruiting 100 patients in four regions between 2024 and 2026 and is investigating EEG, MEG, fMRI, and PET in addition to clinical outcomes to develop a biomarker for psilocybin response.. The results of CAPSI must determine whether a phase III study is feasible and develop a prognostic tool for use in routine care..
The study underwent an extensive peer-review process. The original manuscript was submitted on 18 November 2024; after multiple revisions, the final version was accepted on 27 March 2026 and published on 9 April 2026.. Reviewer reports appreciated the detailed description of the training but pointed out the limited sample size and the need for a control group and more concrete hypotheses..
The study describes, for the first time, a structured training program for nurses providing psychotherapeutic support during psilocybin treatment for depression. Although participants found the training useful, they emphasized the need for more extensive and practical exercises to feel adequately prepared. Objective MITI analyses showed only limited improvements in relational skills; this may be due to the short training duration, the use of nurses (who are normally focused on informational communication), and the small sample size. The CAPSI project itself is ongoing and will yield important data on the effectiveness of psilocybin in cancer patients with depression. For future implementation, more extensive training models, differentiated by professional profile, are needed, and supervision and treatment adherence will need to be monitored during the trial.
This training is part of the larger CAPSI project, a clinical study in Sweden investigating whether a single dose of psilocybin can help with depression in people with cancer. Within this study, participants receive not only a dosing session, but also preparation and integration.
That aligns well with how we at guided truffle sessions with preparation and integration work. The experience itself is only a part of the process; the guidance surrounding it largely determines what someone gets out of it.
The facilitators in this study were primarily nurses without an extensive psychotherapeutic background. They underwent a 15-week training consisting of:
Six online webinars of three hours each
An intensive three-day practical training on location
Self-study and preparation per session
The content covered, among other things:
The effects of psilocybin and the research protocol
Communication skills and therapeutic attitude
Guiding the dosing session, including the use of music
Integration interviews after the experience
What stands out is that the emphasis was strongly on theory via webinars, while the practical component was relatively short.
The outcomes are honest and interesting at the same time. The facilitators themselves indicated that:
She herself reasonably prepared felt, but not completely sure
They mainly needed more practical experience
Physical training was much more valuable than online learning
Objectively speaking, communication skills were assessed using a standardized measurement system (MITI). This revealed:
A slight improvement in collaboration (partnership)
An increase in empathy, but not statistically significant
No major changes in concrete conversational skills
In other words: the training worked a little, but not convincingly.
This research confirms something that has long been visible in practice: guidance is not a side issue, but a core component of the experience.
The participants in this study were accustomed to providing information, as many nurses do. But psychedelic sessions are about something else entirely:
Listening without immediately steering
Leaving space for the other person's process
Working with emotions and inner experience
That requires a different skillset than most medical training programs offer.
Within the field of psychedelics, you currently see two movements emerging:
A model in which the means is central and guidance is minimal
A model in which guidance and process are at least as important
This study shows that good guidance often does not arise spontaneously. It must be actively learned, practiced, and guided.
That aligns with how we view, for example, a truffle ceremony with professional guidance, where preparation, setting, and integration are consciously built up.
Perhaps the most important insight from this research is that knowledge alone is not sufficient. The facilitators clearly indicated that they primarily wanted to:
Practicing with real scenarios
Receiving feedback on their coaching style
Experience for yourself how the process works
This corresponds to what you often see in practice: true competence only arises through experience, not through theory alone.
It is important, however, to put this research in perspective:
Small group of participants (only 9 facilitators)
No control group
Measurements based on role-plays, not real sessions
The results therefore provide primarily an initial indication, not definitive conclusions.
When you translate this research into practice, a few clear lessons emerge:
Guidance is essential for the quality of the experience
Training must be practical and experience-based.
Different backgrounds (such as nurses vs. therapists) require different forms of training.
Supervision and feedback after the first sessions are crucial.
When you translate the insights from this research into practice, it becomes clear where the real quality comes from. Not only from knowledge about psilocybin, but from the combination of training, experience, and collaboration within a team.
Within Triptherapie, this comes together on multiple levels. Part of the team has completed additional training through RINO, providing a solid foundation in conversational skills, attitude, and guidance. At the same time, extensive practical experience has been built up over the past eight years, with more than 3,500 guided psychedelic sessions. This ensures a level of routine and insight that cannot be derived from theory alone.
In addition, a great deal of internal attention is paid to training and development. New supervisors learn not only through theory but also actively gain experience in supervision itself, under the guidance of more experienced colleagues. This aligns perfectly with what the study shows as the necessary next step: learning by doing, with feedback and in-depth study.
What makes Triptherapie extra strong is the diversity and experience within the team. People with diverse backgrounds work here, ranging from psychologists to lifestyle coaches and other people-oriented fields. As a result, there is no single fixed approach, but rather a broad perspective on guidance tailored to the individual undergoing the session.
Taking everything together, you see that the factors identified as important in the research are already integrated within Triptherapie. Training, experience, and a well-aligned team combine to provide guidance that goes beyond merely facilitating a session. It becomes a complete process in which someone is truly guided through what emerges.